VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2014

Nov 7, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2014-11-05

Reporting Person: BOGER JOSHUA S (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-11-05	Common Stock	M	4800	$10.41	Acquired	343695	Direct
2014-11-05	Common Stock	M	1300	$17.16	Acquired	344995	Direct
2014-11-05	Common Stock	M	4400	$35.64	Acquired	349395	Direct
2014-11-05	Common Stock	S	2800	$111.55	Disposed	346595	Direct
2014-11-05	Common Stock	S	6800	$112.39	Disposed	339795	Direct
2014-11-05	Common Stock	S	900	$113.44	Disposed	338895	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-11-05	Stock Option (right to buy)	$10.41	M	4800	Disposed	2015-02-02	Common Stock (4800)	Direct
2014-11-05	Stock Option (right to buy)	$17.16	M	1300	Disposed	2015-07-19	Common Stock (1300)	Direct
2014-11-05	Stock Option (right to buy)	$35.64	M	4400	Disposed	2016-02-01	Common Stock (4400)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	13286	Indirect
Common Stock	172589	Indirect

Footnotes

F1: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.

F2: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3: Open market sales reported on this line occurred at a weighted average price of $111.55 (range $110.97 to $111.96).

F4: Open market sales reported on this line occurred at a weighted average price of $112.39 (range $111.97 to $112.93).

F5: Open market sales reported on this line occurred at a weighted average price of $113.44 (range $113.05 to $113.80).

F6: Common stock held in grantor retained annuity trusts.

F7: Fully vested.